In total, around 270 analyst studies were published on Hannover Re and the insurance sector in the 2016 financial year. By the end of the year 34 analysts had handed down opinions on Hannover Re: 10 analysts (3) recommended the Hannover Re share as “buy” or “overweight”. Altogether 17 opinions (8) were a “hold”, making this the most common. “Underweight” or “sell” recommendations were issued a total of 7 (21) times. Overall, then, the analysts assessed Hannover Re and the share performance more favourably than in the previous year. This development is particularly pleasing in view of what is still a relatively superior valuation measured against peer companies. The analysts’ average price target also moved in a positive direction in the year under review, increasing further from EUR 91.88 at the start of the financial year to EUR 101.34 at year-end.